-
1 Comment
iCAD, Inc is currently in a long term uptrend where the price is trading 9.7% above its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
iCAD, Inc's total revenue rose by 11.4% to $10M since the same quarter in the previous year.
Its net income has increased by 52.1% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 55.1% to $-1M since the same quarter in the previous year.
Based on the above factors, iCAD, Inc gets an overall score of 5/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US44934S2068 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 106M |
|---|---|
| Target Price | 3.75 |
| Beta | 1.4 |
| PE Ratio | None |
| Dividend Yield | None |
iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solutions to identifying pathologies and pinpointing prevalent cancers earlier; and a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging, and computed tomography. In addition, the company suite offers solutions for cancer detection, density assessment, and personalized risk evaluation based on a 2D or 3D mammogram's collection of images. Additionally, its density assessment standardizes and simplifies breast density reporting by algorithmically examining a woman's breast anatomy from the mammogram image. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ICAD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026